Bexarotene, branded as Targretin, is an FDA-approved antineoplastic agent for Cutaneous T cell lymphoma (CTCL), working through a dual mechanism: it inhibits T cell proliferation and induces apoptosis via the p53/p73-dependent pathway [63]. This evidence concerns the gene TP53 and primary cutaneous T-cell non-Hodgkin lymphoma.